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The antifibrotic effects of relaxin in human renal fibroblasts are
mediated in part by inhibition of the Smad2 pathway.
Background. The peptide hormone relaxin has been demon-
strated to exert antifibrotic effects in renal and extrarenal
tissues. The aims of this study were to identify potential anti-
fibrotic effects of relaxin on human renal fibroblasts in vitro and
to analyze their mechanisms.
Methods. All experiments were performed in established re-
nal fibroblast cell lines and in primary cortical fibroblasts. Ef-
fects of relaxin were analyzed on cell proliferation, apoptosis,
activation of renal fibroblasts, synthesis and secretion of colla-
gen type I and fibronectin, as well as on the secretion of matrix
metalloproteinases (MMPs). Effects on transforming growth
factor-b1 (TGF-b1) receptor binding were analyzed by flow
cytometry and on TGF-b1 signal transduction by immunoblot
analyses for Smad4 and 7, translocation from cytosol to nucleus
for Smad2 and 3 as well as for phosphorylated and unphospho-
rylated forms of p38, c-Jun NH2 terminal kinase (JNK) and
extracellular-regulated protein kinase (ERK). Finally, specific
siRNAs for Smad2 and 3 were applied to assess the signal trans-
duction pathway.
Results. After stimulation with relaxin, tyrosine phospho-
rylation of a 220 kD protein was demonstrated, indicat-
ing interaction with the receptor. Relaxin had only modest
inhibitory effects on cell proliferation, and no effects on apop-
tosis. Conversely, relaxin exerted robust effects on TGF-b1–
induced fibroblast to myofibroblast transformation as well as
on matrix synthesis and secretion even at the smallest dose
tested. The secretion of MMP-2 and MMP-9 was induced no-
ticeably by all investigated relaxin concentrations. TGF-b1
receptor binding was not influenced by relaxin; however, it pre-
vented Smad2 phosphorylation, translocation to nucleus, and
complex formation between Smad2 and 3 indicating a possible
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interaction with TGF-b1 signaling. These findings were corrob-
orated by studies using siRNAs to Smad2 and 3 where siRNA
to Smad2 but not to Smad3 inhibited the TGF-b1 induction
of fibronectin synthesis. There was no influence of relaxin on
intracellular Smad3, Smad4, and Smad7 translocation or phos-
phorylation of mitogen-activated protein (MAP) kinases.
Conclusion. Relaxin is a potent inhibitor of TGF-b1–induced
extracellular matrix (ECM) synthesis and secretion as well as
fibroblast activation. Furthermore, it induces ECM degradation
by induction of MMP-2 and MMP-9. These effects are mediated,
at least in part, by inhibition of TGF-b1 signaling.
The typical morphologic correlate of end-stage renal
failure is interstitial fibrosis, tubular atrophy, and dilata-
tion. Renal fibrosis is mainly characterized by an acti-
vation and proliferation of interstitial fibroblasts and by
an excessive synthesis and accumulation of extracellu-
lar matrix (ECM) components, including fibronectin and
collagen types I, III, and IV along with a decreased rate
of ECM degradation [1]. This ECM degradation is often
inhibited during fibrogenesis due to the up-regulation of
tissue inhibitor of matrix metalloproteinase 1 (TIMP-1)
and/or a decreased activity of matrix metalloproteinase
(MMP). Cytokines such as transforming growth factor-
b1 (TGF-b1), connective tissue growth factor (CTGF),
platelet derived growth factor (PDGF), fibroblast growth
factor 2 (FGF-2), and angiotensin II (Ang II) play impor-
tant roles in the process of fibrogenesis [2]. TGF-b1 is cur-
rently viewed as the most important fibrosis-promoting
cytokine [3]. It is responsible for several profibrotic
events during fibrogenesis, including ECM synthesis in
fibroblasts and tubular epithelial cells, differentiation of
fibroblasts into myofibroblasts, epithelial-mesenchymal
transformation of tubular epithelial cells, and inhibition
of matrix degradation by inhibiting the expression of
MMPs and up-regulating the expression of TIMPs. In-
creased expression has been demonstrated in a number of
animal models associated with progressive renal disease
including anti-Thy1.1 nephritis [4], diabetic nephropa-
thy [5], Heyman nephritis [6], and obstructive nephropa-
thy [7]. TGF-b signal transduction is mainly regulated
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via the Smad proteins, the receptor mediated Smad2,
Smad3, the common mediator Smad, Smad4, and the in-
hibitory Smad7 [8]. Furthermore, mitogen-activated pro-
tein (MAP) kinase pathways play an important role for
TGF-b signal transduction [9].
Interstitial scarring often progresses despite resolution
of the primary disease process. Recently, a number of po-
tential factors have emerged with the potential to possibly
reverse fibrotic disease in the kidney, including hepato-
cyte growth factor (HGF) [10] and bone morphogenetic
protein-7 (BMP-7) [11]. However, these substances have
not been tested in clinical studies and additional ap-
proaches are needed. Another potential candidate for a
novel therapeutic approach to progressive renal disease
is relaxin. It is a peptide hormone with a molecular weight
of 6 kD and a member of the insulin-like growth factor
(IGF) family. Like insulin, relaxin is composed by two
disulfide-linked chains, the A and B chains [12]. It is pre-
dominantly produced by the corpus luteum during preg-
nancy whereby serum levels in pregnant women range
from 0.2 to 1.2 ng/mL [13]. The primarily biologic func-
tions of relaxin are the widening of the birth channel in
preparation of birth and the renal vasodilation and hyper-
filtration during pregnancy [14]. In humans two genes (H1
and H2) code for functional relaxin. However, H2 relaxin
is the principal expression product in vivo. Relaxin has
already demonstrated promising antifibrotic potential in
vitro and in vivo. In dermal and pulmonary as well as in
hepatic fibroblasts recombinant human (rh) relaxin pre-
vented TGF-b–induced collagen synthesis [15–17]. Fur-
thermore, in pulmonary fibroblasts, relaxin inhibited the
fibronectin synthesis and stimulated MMP secretion [16].
Relaxin deficiency in mice results in an age-related pro-
gression of lung fibrosis [18]. In vivo relaxin showed antifi-
brotic properties in models of pulmonary [15] and renal
fibrosis [19, 20]. Furthermore, it reduced skin thickening
and improved mobility in a clinical trial in scleroderma
patients [21]. However, the mechanisms of its actions are
largely unknown.
The aims of this study were to investigate the effects
of relaxin on cell growth and activation, matrix synthesis,
and degradation in human renal fibroblasts and to iden-
tify the intracellular signaling mechanism of these pro-
cesses. We demonstrate that relaxin influences fibroblast
proliferation only modestly but has robust inhibitory ef-
fects on fibroblast activation and ECM synthesis while
stimulating matrix degradation. These effects are medi-
ated by the prevention of Smad2 phosphorylation and
complex formation with Smad3, whereas no interference
with the MAP kinase pathway was observed.
METHODS
Materials
rhrelaxin was a generous gift from Dr. Unemori
(Connectics Corp., Palo Alto, CA, USA), rhTGF-b1
was purchased from R&D Systems (Minneapolis, MN,
USA). The following mouse monoclonal antibodies
were used for cell characterization: anticollagen type
I [also used for enzyme-linked immunosorbent assay
(ELISA)], anticollagen type III (both from Southern
Biothechnology, Birmingham, AL, USA), anticytok-
eratin (Dako, Carpinteria, CA, USA), antivimentin
(Boehringer Mannheim, Mannheim, Germany), an-
tifactor VIII (Dako), antihuman leukocyte antigen
(anti-HLA-DR) (Dako), anti-a-smooth muscle actin
(anti-a-SMA) (Paesel and Lorei, Wiesbaden, Germany),
anti-CD44 (Pharmingen, San Diego, CA, USA), anti-
CD54, and anti-CD68 (Dako). Rabbit polyclonal an-
tibody to collagen type I from Biotrend (Cologne,
Germany) was used for immunoblot analyses; rabbit
polyclonal antibody to fibronectin (Sigma Chemical Co.,
St. Louis, MO, USA) was used for ELISA as well as
for immunoblots. Antirabbit IgG alkaline phosphatase
(AP) and antisheep/goat IgG AP, Fab fragments (both
from Boehringer Mannheim, Mannheim, Germany)
were used as secondary antibodies for ELISA. Mouse
polyclonal anti-MMP-1 was purchased from Oncogene
(Boston, MA, USA) and rabbit polyclonal anti-MT-
MMP-1 from Calbiochem-Novabiochem (Nottingham,
UK). The rabbit antibodies to extracellular-regulated
protein kinase 1/2 (ERK1/2) and c-Jun NH2 terminal
kinase 1/2 (JNK1/2), the mouse monoclonal antibod-
ies to phosphorylated JNK1/2, p38 MAP kinase, and
phosphorylated p38 MAP kinase as well as the goat
polyclonal antibody to phosphorylated ERK1/2 were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), as was the donkey antigoat-horseradish peroxi-
dase (HRP) secondary antibody for immunoblots. Re-
combinant antiphosphotyrosine HRP, goat polyclonal
Smad7, and mouse polyclonal Smad4/DPC4 were used
for immunoblots and purchased from Transduction Lab-
oratories (Lexington, KY, USA). The rabbit polyclonal
antibody to phosphorylated Smad2 was a kind gift
from Serhiy Souchelnytski (Ludwig Institute for Cancer
Research, Uppsala, Sweden) and the rabbit poly-
clonal antibody to phosphorylated Smad3 was purchased
from Cell Signaling (Beverly, MA, USA). The mouse
monoclonal antibody to a-SMA was purchased from
Progen (Heidelberg, Germany). The mouse antibody
to caspase 3 was a friendly gift from Dr. Schweyer
(Department of Pathology, Georg-August-University,
Goettingen, Germany). As secondary antibodies for im-
munofluorescence stainings served rabbit antimouse flu-
orescein isothiocyanate (FITC) and rabbit antimouse
Rhodamin from Dianova (Hamburg, Germany). Trypsin
ethylenediaminetetraacetic acid (EDTA), Dulbecco’s
modified Eagle’s medium (DMEM), Iscove’s modified
Eagle’s medium (IMDM), and fetal calf serum (FCS)
were obtained from Gibco Ltd. (Paisley, Scotland). Cell
culture dishes were from Becton Dickinson (Franklin
Lakes, NJ, USA).
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Cell culture and quantitation of a-SMA–positive cells
Human renal fibroblast cell lines Tk 173 (normal kid-
ney derived) and Tk 188 (from a kidney with tubu-
lointerstitial fibrosis) have been described previously
[22]. These cells were cultured in DMEM containing
10% FCS, 1% L-glutamine (both from Gibco) and 5
lg/mL M-plasmocin to avoid mycoplasma contamination
(Paesel and Lorei). Primary renal fibroblasts were iso-
lated from human kidney biopsies. Isolation and charac-
terization were performed as described before [23]. Cells
that were positive for vimentin, CD44, CD54, a-SMA,
and the collagen types I and III, and negative for cytok-
eratin, factor VIII, and major histocompatability com-
plex (MHC) class II were considered to be fibroblasts
and used for induction assays in passages 2 to 8. Addi-
tional staining with the Hoechst dye H33258 (Boehringer
Mannheim) was performed to facilitate cell counting. Pri-
mary cortical fibroblasts Tk 489 were established from a
61-year-old female with membranous gomerulonephritis
without interstitial involvement, Tk 461 fibroblasts were
cultured from a biopsy of a 25-year-old female with IgA
nephritis and tubulointerstitial fibrosis involving 30% of
the interstitium.
Quantitation of a-SMA expression was performed as
described previously [24]. Briefly, cells were counted and
the relative percentage of positive cells determined by
a blinded investigator after stimulation with 10 ng/mL
TGF-b1 and relaxin in concentrations of 0.1, 1, and
10 ng/mL for 48 hours. Stimulation with TGF-b1 alone
served as positive control. Cells with the typical a-
SMA structure were considered to be a-SMA–positive,
whereas cells with faint green halo were deemed negative.
Tyrosine phosphorylation
Since the exact nature of the relaxin receptors has not
been elucidated, we examined a possible specific cellu-
lar response of human renal fibroblasts to relaxin stim-
ulation. Fibroblasts were stimulated with relaxin (0.1,
1, and 10 ng/mL) for 15, 30 and 45 minutes and pro-
tein was isolated as described before [23]. Briefly, fi-
broblasts were lysed with a detergent based buffer and
100 lg of cellular protein were run on a 7.5% sodium do-
decyl sulphate-polyacrylamide gel elctrophoresis (SDS-
PAGE) gel and transferred to a nitrocellulose membrane
(HybondTM ECLTM) (Amersham, Arlington Heights, IL,
USA) by wet electroblotting. To prevent degradation
of phosphorylated proteins the tyrosine phosphatase in-
hibitor sodium vanadate (0.5 mmol/L) was added to the
lysis buffer. Membranes were stained with Ponceau red
to control for equal loading and transfer. After block-
ing [phosphate-buffered saline (PBS) + 0.1% Tween +
5% dry milk] for 6 hours, the membrane was incubated
with the primary antibody (antiphosphotyrosine anti-
body 1:500) followed by the secondary antibody (antirab-
bit HRP antibody) (1:3000). Positive reaction products
were identified by chemiluminescence detection with en-
hanced chemiluminescence (ECL)+ (Amersham). Anti-
bodies were diluted in PBS containing 3% bovine serum
albumin (BSA).
Effects on proliferation, apoptosis, and necrosis
Proliferation studies were performed using cell counts
and nonradioactive bromodeoxyuridine (BrdU) incorpo-
ration assays (Amersham) as described before [23]. For
cell count experiments, Tk 173 and Tk 188 fibroblasts
were plated at 1 × 105 cells per well in a 24-well mi-
crotiter plate containing DMEM medium with 10% FCS
and incubated overnight. Cells were made quiescent by
incubation with FCS-free Iscove’s medium for 24 hours.
Subsequently, cells were incubated with various additives
for additional 72 hours. IMDM medium alone served as
negative, IMDM medium containing 10% FCS as pos-
itive control. After trypsination, cells were stained with
trypane blue and counted using a Neubauer chamber. All
experiments were repeated three times.
For BrdU incorporation assay, Tk 173 and Tk 188 fi-
broblasts were plated at 4 × 103 cells per well in 96-well
microtiter plates containing DMEM medium with FCS
and incubated overnight. Cells were subsequently made
quiescent as described above. Medium containing 10%
FCS was used as positive control or FCS+ relaxin. IMDM
without additives served as negative control. Relaxin was
added in concentrations of 0.1, 1, and 10 ng/mL. Prolif-
eration was measured after 24, 48, and 72 hours. Opti-
cal densities were determined photometrically at 405 nm
(Dynatech MR 4000) (Denkendorf, Germany). All ex-
periments were performed in triplicates and repeated five
times.
Apoptosis and necrosis rates were investigated in Tk
173 and Tk 188 fibroblasts after incubation with either
IMDM (control), TGF-b1, or different concentrations of
relaxin for 72 hours. Apoptosis was detected by immuno-
cytochemical staining for caspase 3. After cytospin, cells
were air dried, briefly fixed in acetone/methanol (1:1) and
stained for caspase 3 using a modified APAAP method
as described elsewhere [25]. Using fast red as peroxidase
substrate resulted in a red signal in positively stained cells.
The number of positively stained cells was counted and
results are shown in percent of total cell number.
Necrosis assay was performed by detection of propid-
ium iodide by FACS analysis. After trypsination, cells
were counted, and 5 × 105 cells per sample were in-
cubated with phycoerythrin-conjugated antipropidium
iodide antibody for 15 minutes, washed twice before
they were counted by a FACS Calibur Flow Cytometer
(Becton Dickinson). Results are given in percentage of
control IMDM.
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Matrix secretion and synthesis
ELISAs and immunoblots were performed for colla-
gen I and fibronectin, the main components of the inter-
stitial matrix. ELISAs of supernatants were performed
as described before [23]. A total of 8 × 103 cells were
plated per well, and cells were again made quiescent by
incubation in serum-free IMDM. After 24 hours, IMDM
was replaced by medium containing 1 ng/mL TGF-b1 ei-
ther alone (as positive control) or in combination with
relaxin. IMDM without additives served as negative con-
trol. Relaxin was again added in concentrations of 0.1,
1, and 10 ng/mL. Ascorbic acid (50 lg/mL) and propi-
onitrile (50 lg/mL) were added in experiments evalu-
ating collagen secretion. After 48 hours of incubation,
supernatants were transferred to a MicroliteTM plate and
incubated overnight at 37◦C. Plates were subsequently
dried for 2 hours and blocked with PBS/3% dried milk.
Incubation with 50 lL/well of the primary antibody (an-
ticollagen type I in a dilution of 1:300 and antifibronectin
antibody at 1:5000 in PBS/0.1% BSA) for 2 hours was
followed by washing with PBS/0.1% Tween and incuba-
tion with the secondary antibody (antirabbit IgG AP and
sheep/antigoat IgG AP, both 1:1000 in PBS/BSA). After
three final wash steps, 100 lL/well Boehringer Mannheim
(BM) chemiluminescence ELISA substrate (Boehringer
Mannheim) was added. Chemiluminescence was then
measured in a luminometer (Mikrolumat CB 96P)
(Berthold, Bad Wildbad, Bermany) using MikroWinTM
software (Mikrotek, Overath, Germany). Nonspecific
binding was determined by incubation with the secondary
antibody only. The value was normally less than 5% of the
total chemiluminescence and was subtracted from each
assay. All experiments were performed in triplicates and
repeated three times. Standardization was obtained for
the collagen type I ELISA using human type I collagen
(Becton Dickinson). The limit of detection was 1 ng/mL,
with a working range of 10 to 1000 ng/mL. Human fi-
bronectin (Sigma Chemical Co.) served as standard for
the fibronectin ELISA. The working range of hat ELISA
was 0.1 to 10 lg/mL, with a limit of detection of 10 ng/mL.
The influence of relaxin on the matrix synthesis was
evaluated by immunoblot analyses for collagen type I
and fibronectin. Cells were treated in flasks under condi-
tions as described above and proteins were isolated after
48 hours. Specificity of the antibodies was determined as
described [23].
Measurement of TGF-b1 receptor binding
To investigate TGF-b1 receptor binding a Fluo-
rokineTM Cytokine Flow Cytometry Kit was used. Exper-
iments were performed according to the manufacturer’s
instructions with some modifications. Cells were culti-
vated as described above. After trypsination, cells were
incubated in DMEM for 6 hours on a rocker platform to
enable receptor regeneration. The rocker platform was
used to prevent reattachment to the substrate. Then cells
were washed in PBS and resuspended at 4 × 106 cells per
mL in PBS or PBS + relaxin (0.1, 1, and 10 ng/mL, re-
spectively). Twenty-five microliters of each solution was
incubated with 12.5 ng of biotinylated TGF-b1 for 60
minutes at 4◦C. Then 10 lL avidin FITC reagent was
added and incubated for 30 minutes at 4◦C. Probes were
washed twice, resuspended in 200 lL of RDF1 buffer and
measured at 488 nm in a FACS Calibur Flow Cytometer
(Becton Dickinson). Biotinylated soy bean trypsin in-
hibitor served as negative control. Specificity was con-
trolled by incubation of 40 lg antihuman-TGF-b1 with
12.5 ng biotynilated TGF-b1 for 15 minutes at room tem-
perature and identical treatment.
Zymography
Gelatine zymography was used to evaluate the effects
of relaxin on gelatinase (MMP-2 and MMP-9) expres-
sion. Briefly, cells were plated at a density of 8 × 104/mL
and growth-arrested in Iscove’s medium for 24 hours
before incubation with relaxin (0.1, 1, and 10, ng/mL)
in the presence or absence of 10% FCS or neutralizing
TGF-b-antibody, respectively, for 48 hours. Cell super-
natants were 10× concentrated and equal amounts of
total protein were loaded on SDS gel containing 1.0 mg
gelatin per mL and electrophoresis on nonreducing SDS-
10% polyacrylamide gels (Bio-Rad) was performed. Af-
ter 30 minutes, incubation in renaturation buffer contain-
ing 2.5% Triton X-100, gelatinolytic activity was detected
by an 18-hour incubation step in 5 mmol/L CaCl2, 50
mmol/L Tris/HCl, pH 7.5, at 25◦C before Coomassie bril-
liant blue staining of the gels (0.5% Coomassie blue in
40% methanol/10% acetic acid for 1 hour). Destaining
was performed in the same buffer devoid of Coomassie
blue for 15 minutes. The presence of the MMPs was indi-
cated by an unstained proteolytic zone of the substrate.
Molecular sizes of the bands displaying enzymatic activity
were identified by comparison to standard proteins and
to purified MMPs (both from Calbiochem). Quantifica-
tion was achieved by densitometric analysis as described
above.
Immunoblot analyses for Smad2, 3, 4, 7, phosphorylated
Smad2, phosphorylated Smad3, JNK, ERK, p38,
phosphorylated JNK, phosphorylated ERK, and
phosphorylated p38 MAP kinase
Cells were solubilized and cytosolic proteins were ex-
tracted by addition of cytosolic lysis buffer [10 mmol/L
Hepes, 1.5 mmol/L MgCl2, 10 mmol/L KCl, 1 mmol/L
phenylmethylsulfonyl fluoride (PMSF), 0.1% NP-40, pH
7.9] for 10 minutes on ice. Solubilized proteins were iso-
lated by centrifugation with 3500 U/min for 4 minutes
and nuclear proteins were extracted out of the pellet by
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adding of nuclear lysis buffer (20 mmol/L Hepes, 420
mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA,
and 25% glycerol, pH 7.9) for 30 minutes on ice. Total
cellular proteins were isolated as described before. Solu-
bilized proteins were extracted by additional centrifuga-
tion with 10.000 U/min for 10 minutes at 4◦C.
The Western blot analyses for Smad2 were performed
as described above. For phosphorylated Smad2 analy-
ses, cells were stimulated for 60 minutes with 10 ng/mL
TGF-b1 ± relaxin (0.1, 1, and 10 ng/mL). Immunoblots
were performed as described above. Rabbit antiphos-
phorylated Smad2 antibody was diluted 1:600 and rabbit
antiphosphorylated Smad3 1:1000, secondary antirabbit-
HRP antibody 1:3000. The HRP-conjugated recombinant
antiphosphotyrosine antibody was diluted 1:500 in PBS
containing 3% BSA.
Immunoprecipitation
Proteins were isolated as described above and 50 lg
protein per sample were incubated with anti-Smad2 or
anti-Smad3 antibody, respectively, for 1 hour, followed
by immunoprecipitation with agarose A overnight at
4◦C. After five washes, the immunoprecipitates were
boiled for 3 minutes in Laemmli sample buffer. The re-
sulting precipitated complexes were separated on SDS-
polyacrylamide gels, blotted and complex-bound Smad3
(Smad2/3 complex) or phosphorylated Smad3 were de-
tected by a specific antibody and quantification was
achieved by densitometric analysis as described above.
Smad2 and Smad3 siRNA transfection and immunoblot
Tk 173 and Tk 188 were plated on a 6-well plate in a
density of 4 × 105 cells per well and grown for 48 hours.
Then the medium was changed and cells were transfected
with Smad2 siRNA SMART Pool (Upstate Cell Sig-
nalling Solutions, Waltham, MA, USA) or Smad3 siRNA
(Ambion, Austin, TX, USA) using RNAiFectTM Trans-
fection Reagent (Qiagen, Valencia, CA, USA) follow-
ing manufacturer’s instructions. Cells were left untreated
(negative control) or stimulated with 10 ng/mL TGF-
b1 in the presence or absence of 10 ng/mL relaxin for
48 hours. Cells were lysed and protein isolated as de-
scribed above. Effective transfection was documented by
Western blot analysis for Smad2 or Smad3, respectively.
Effects of TGF-b1 on synthesis of fibronectin in the pres-
ence or absence of 10 ng/mL relaxin in transfected and
untransfected cells were analyzed by immunoblots as de-
scribed above.
Statistical analysis
All values are expressed as mean ± SEM. One-way
analysis of variance (ANOVA) was used to determine sta-
tistical differences between growth factor treated groups
C 15’ 30’ 45’ 15’ 30’ 45’ 15’ 30’ 45’
0.1 ng/mL RLX 1 ng/mL RLX 10 ng/mL RLX
220 kD
Fig. 1. Relaxin stimulates the tyrosine phosphorylation of a 220 kD
protein. After stimulation of Tk 173 fibroblasts with relaxin (RLX) (0.1,
1, and 10 ng/mL) for 15, 30, and 45 minutes a tyrosine phosphorylation
of a 220 kD protein was seen. This protein may represent a relaxin
receptor. One representative blot is shown.
and controls using Sigma-StatTM-software 2.03 (Jandel
Scientific, San Rafael, CA, USA). Bonferroni’s method
was used to control for multiple testing. P values < 0.05
were considered significant.
RESULTS
Stimulation with relaxin results in tyrosine
phosphorylation in human renal fibroblasts
Relaxin is an insulin-like hormone. Therefore, its re-
ceptor may be, like the insulin receptor, a tyrosine kinase.
Relaxin did induce tyrosine phosphorylation in all exam-
ined cells. In Tk 173 fibroblasts a significant increase in
tyrosine-phosphorylation was seen at relaxin dosages of
1 ng/mL (172.6 ± 16.0% of control after 30 minutes) and
10 ng/mL (151.6 ± 12.2% of control after 45 minutes).
Figure 1 displays a characteristic blot.
Relaxin inhibits proliferation of human fibroblasts,
but has no effect on either apoptosis or necrosis
The peptide hormone relaxin significantly decreased
cell count to 30 ± 13% in Tk 173 or 58 ± 16% in Tk 188
of controls after 72 hours. The effects were reproducible
in Tk 188 fibroblasts in the presence of 10% FCS, whereas
in Tk 173 they were not (Fig. 2A). Proliferation rate of
human fibroblasts were decreased after stimulation with
relaxin after 24, 48, and 72 hours at all investigated con-
centrations (Fig. 2B). However, these effects were not
robust and a significant inhibition was only found in Tk
173 cells after 72 hours of stimulation with 0.1 ng/mL
relaxin (−10.8 ± 3.7%). The maximum inhibition in Tk
188 was also seen after 72 hours of stimulation with 10
ng/mL relaxin (−22.0 ± 12.6%). There were no effects
on apoptosis or necrosis rates (data not shown).
Relaxin inhibits TGF-b1–induced fibroblast activation
into myofibroblasts
The differentiation of fibroblasts into myofibroblasts is
thought to represent one of the key steps during fibro-
genesis. Thus, in order to determine if relaxin influences
this process in vitro, primary fibroblasts Tk 461 were in-
cubated with TGF-b1 ± relaxin as described above and
the number of a-SMA–positive cells was determined.
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Fig. 2. Effects of human recombinant relaxin (rhRLX) on cell count
(A) and proliferation (B) of immortalized normal kidney-derived (Tk
173) and fibrotic kidney-derived (Tk 188) cortical human renal fibrob-
lasts. Relaxin was added in concentrations of 0.1, 1 and 10 ng/mL for 72
hours. Cell growth was either determined by cell count (A) or bromod-
oxyuridine (BrdU) incorporation (B). Relaxin showed antiproliferative
effects which were more prominent in Tk 188 fibroblasts. Values are
given in percentage of negative control (NC is Iscove’s medium alone)
(A) or positive control [(PC is 10% fetal calf serum (FCS)] (B) and are
the mean of five (Tk 173) and six (Tk 188) experiments. All experiments
were performed in triplicates. P values were significant against nega-
tive control (A) or positive control (B). ∗P < 0.05 vs. negative control;
∗∗P < 0.01 vs. negative control; §P < 0.05 vs. 10% FCS.
Under basal conditions (IMDM/1% FCS) the number
of a-SMA–positive cells was 11.5 ± 1.7%. Stimulation
with 10 ng/mL TGF-b1 raised the number of a-SMA–
positive cells to 33.7 ± 1.4%. Relaxin was able to reverse
the TGF-b1–induced increase of a-SMA–positive cells in
all investigated concentrations. The maximum inhibition
was found after stimulation with 1 ng/mL relaxin (13.8 ±
1.6% a-SMA–positive cells). Figure 3 illustrates a typical
staining pattern.
Relaxin has robust antifibrotic effects by inhibiting
the TGF-b1–induced ECM synthesis and secretion
To study the interactions between relaxin and the
TGF-b1–induced ECM synthesis immunoblot analyses
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Fig. 3. Expression of a-smooth muscle actin (a-SMA) in primary cor-
tical fibroblasts. The number of a-SMA–positive cells was determined
after incubation with 10 ng/mL transforming growth factor-b1 (TGF-
b1) and three different concentrations of relaxin (RLX) (0.1, 1, and 10
ng/mL) for 48 hours. Single stimulation with TGF-b1 served as posi-
tive control (PC), Iscove’s medium as negative control (NC). (A) gives
a representative example of the positive control, (B) summarizes the
findings graphically. Relaxin reduced a-SMA expression at all investi-
gated concentrations significantly. ∗∗P < 0.01 vs. positive control.
for type I collagen and fibronectin were performed. The
ECM secretion was investigated by ELISAs for type I col-
lagen and fibronectin. The TGF-b1–induced ECM syn-
thesis was strongly inhibited by relaxin in all investigated
cell lines. In Tk 173 the maximum inhibition for collagen
I synthesis was found at a dosage of 0.1 ng/mL relaxin
(−52.7 ± 6.7%), in Tk 188 at a dosage of 1 ng/mL re-
laxin (−25.2 ± 8.4%) (Fig. 4). The fibronectin-synthesis
was highly significant inhibited at all investigated relaxin
doses as well as in all investigated cell lines [Tk 173 and
Tk 188 (Fig. 5A) and in primary kidney fibroblasts Tk 489
and Tk 461 (data not shown)]. The maximum inhibition
of fibronectin synthesis was seen at dosages of 1 ng/mL re-
laxin for Tk 461(−34.4 ± 5.6%) and 10 ng/mL relaxin for
Tk 173 (−55.0 ± 4.6%), Tk 188 (−51.3 ± 2.4%), and Tk
489 (−40.5 ± 5.7%). However, relaxin alone had no ef-
fect on constitutive fibronectin synthesis in neither FCS-
starved nor in unstarved Tk 173 and Tk 188 fibroblasts
(Fig. 5B).
The TGF-b1–induced secretion of collagen type I was
inhibited by relaxin in both cell lines (Fig. 6A and B).
In the supernatants of the positive control (1 ng/mL
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Fig. 4. Inhibition of collagen type I synthesis in Tk 173 (dark shad-
ing) and Tk 188 cells (white shading). The effect of relaxin (RLX) on
collagen type I synthesis (alpha 1 and alpha 2 chain) was examined by
immunoblot analyses of cellular protein after incubation with 1 ng/mL
transforming growth factor-b1 (TGF-b1) and three different concen-
trations of relaxin (0.1, 1, and 10 ng/mL) for 48 hours. Single stimulation
with TGF-b1 served as positive control (PC), Iscove’s medium as neg-
ative control (NC). Values are given in percentage of positive control
and are the mean of four independent experiments. At this figure also
one representative blot is shown. ∗P < 0.05; ∗∗P < 0.01.
TGF-b1) 649.9 ± 119.2 ng/mL (Tk 173) and 2072.2 ±
627.8 ng/mL (Tk 188) collagen I were measured. The
most visible reduction of secreted collagen I was found at
a dosage of 1 ng/mL relaxin (298.5 ± 84.3 ng/mL for Tk
173 and 651.3 ± 310.4 ng/mL for Tk 188). Likewise, the
secretion of fibronectin was inhibited by relaxin (Fig. 6C
and D). In Tk 173 the amount of fibronectin in the super-
natants of the positive control was 1039.6 ± 375.7 ng/mL,
in Tk 188 it was 659.59 ± 59.0 ng/mL. The strongest reduc-
tion of the fibronectin concentration was found at dosages
of 0.1 (Tk 173 460.9 ± 128.6 ng/mL) and 10 ng/mL RLX
(Tk 188 372.5 ± 39.8 ng/mL).
Relaxin stimulates secretion of MMP-2 and MMP-9 in
renal fibroblasts
The effects of relaxin on matrix-degrading enzymes
were studied by gel zymography analyses. Relaxin dis-
played robust antifibrotic effects by inducing the secre-
tion of MMP-2 and MMP-9 in Tk 173 and Tk 188 fibrob-
lasts (Fig. 7). In both cell lines, MMP-2 secretion was
induced highly significantly at all investigated relaxin
doses. The most robust increase was seen after stimula-
tion with 10 ng/mL relaxin (131.1 ± 5.7% of control in Tk
173 and 167.0 ± 15.0% of control in Tk 188). Moreover,
in Tk 188 incubation with 1 ng/mL relaxin induced a sig-
nificant induction of the MMP-9 secretion 191.7 ± 22.1%
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Fig. 5. Inhibition of relaxin (RLX) to transforming growth factor-b1
(TGF-b1)–induced fibronectin synthesis in Tk 173 and Tk 188 human
renal fibroblasts. The effect of relaxin on fibronectin synthesis was ex-
amined by immunoblot analyses of cellular protein after incubation
with 10 ng/mL TGF-b1 and three different concentrations of relaxin
(0.1, 1, and 10 ng/mL) for 48 hours. Single stimulation with TGF-b1
(10 ng/mL) served as positive control (PC), Iscove’s medium as neg-
ative control (NC). Relaxin had robust inhibitory effects on TGF-b1
fibronectin synthesis in both, Tk 173 (dark shading) and Tk 188 (white
shading). Values are given in percentage of positive control and are the
mean of nine (Tk 173) and seven (Tk 188) independent experiments
(A). Relaxin alone had no effects on fibronectin synthesis neither in
fetal calf serum (FCS)-starved nor in unstarved Tk 173 or Tk 188 fi-
broblasts (B). ∗P < 0.05; ∗∗P < 0.01.
of control. In Tk 173 the strongest increase of MMP-9 se-
cretion was demonstrated by stimulation with 10 ng/mL
relaxin (129.7 ± 20.8% of control); however, this effect
was not significant.
Additionally, relaxin induced MMP-2 and MMP-9
secretion was determined in unstarved fibroblasts un-
der equal conditions. Relaxin exerted a significant up-
regulation of both MMP-9 (+68 ± 5.1% vs. control in Tk
173 and +55.5 ± 5.0% vs. control in Tk 188 fibroblasts)
(P < 0.05) and MMP-2-activity (+107 ± 8.6 vs. control
in Tk 188) (P < 0.05) after stimulation with 10 ng/mL
relaxin (data not shown).
To prove the expression of MMP-1 immunoblot, casein
gel zymography, and ELISA analyses were performed.
MT-MMP-1 expression was examined by immunoblots.
However, both MMP-1and MT-MMP-1 expression could
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Fig. 6. Influence of relaxin (RLX) on colla-
gen type I and fibronectin secretion of human
renal fibroblasts. The effect of relaxin trans-
forming growth factor-b1 (TGF-b1)–induced
extracellular matix (ECM) secretion was
evaluated by enzyme-linked immunosorbent
assay (ELISAs) for collagen type I and fi-
bronectin of cell supernatants. Experiments
were performed after stimulation with 10
ng/mL TGF-b1 and three different concentra-
tions of relaxin (0.1, 1, and 10 ng/mL) for 48
hours. Single stimulation with TGF-b1 served
as positive control (PC), Iscove’s medium as
negative control (NC). Relaxin had legible in-
hibitory effects on collagen type I secretion of
Tk 173 (A) and Tk 188 (B) as well as on fi-
bronectin secretion of Tk 173 (C) and Tk 188
(D). Values are the mean of six independent
experiments. ∗P < 0.05; ∗∗P < 0.01.
not be demonstrated in the human renal fibroblast cell
lines Tk 173 and Tk 188 (data not shown).
Relaxin does not interact with TGF-b1 action by affecting
its receptor binding
Possible effects of relaxin on TGF-b1 receptor binding
were examined by flow cytometric analyses. Relaxin does
not affect TGF-b1 receptor binding in any investigated
relaxin dose (data not shown).
In Tk 173 and Tk 188 fibroblasts, relaxin effects the TGF-
b1 signal transduction via Smad-proteins by inhibiting
Smad2 but not Smad3 pathway
In order to examine the mechanisms of relaxin action,
the effects of relaxin on different TGF-b1 signal transduc-
tion pathways was investigated. Therefore immunoblot
analyses for common Smad4 and inhibitory Smad7 and,
moreover, for phosphorylated Smad2, translocation of
Smad2 and 3 from cytosol to nucleus, and, for heteromeric
formation between Smad2 and 3 after immunoprecipita-
tion were performed. In addition, effects of relaxin on
MAP kinase pathway were investigated by immunoblots
for the unphosphorylated and phosphorylated forms of
the MAP kinases JNK1/2, ERK1/2, and p38.
Smad2 phosphorylation was inhibited by relaxin at all
investigated relaxin doses (Fig. 8A). The strongest inhi-
bition was seen at a concentration of 1 ng/mL relaxin
(−24.3 ± 10.7% vs. positive control). In contrast, re-
laxin had no effects on Smad3 phosphorylation (Fig. 8B).
Since the antiphosphorylation Smad3 antibody cross-
reacts with pSmad1, 5, and 8, we precipitated proteins
prior to immunoblot analysis with a specific antibody
to Smad3. Additionally, relaxin significantly inhibited
translocation of Smad2 from cytosol to nucleus, with
a maximal inhibition at a dosage of 10 ng/mL relaxin
(−47.3 ± 7.3% vs. positive control in Tk 173 and −61.0 ±
9.2% vs. positive control in Tk 188 fibroblasts) (Fig. 9A).
Since phosphorylated Smad2 forms a heteromeric com-
plex with Smad3 and 4, we investigated whether this com-
plex formation was inhibited by relaxin. Consecutively,
reduction of Smad2 phosphorylation was associated with
a reduction of active complex bound Smad3 as it has been
detected by immunoblot after immunoprecipitation for
Smad2 in Tk 188 cells (Fig. 9B). The strongest inhibition
was seen at the dosage of 0.1 ng/mL relaxin (−26.3 ±
14.1% vs. positive control). Conversely, relaxin did have
no effect on Smad3 translocation (data not shown) and
intracellular Smad7 concentrations (Fig. 9C).
To give further evidence that the effects of relaxin are
mediated by Smad2, and not Smad3 inhibition, we com-
pared its effects with those of inhibitory RNA to Smad2
or Smad3. Successful transfection was demonstrated by a
reduction of total Smad2 or Smad3, respectively, of more
than 80% compared to controls (Fig. 10A). Fibronectin
synthesis was chosen as an easy read-out system. Both,
relaxin (10 ng/mL) and siRNA to Smad2, significantly
blocked TGF-b1–induced fibronectin up-regulation by
−66.33 ± 18.0% using relaxin (P < 0.05 vs. positive con-
trol) and –80.67 ± 21.1% using siRNA to Smad2 (P <
0.05 vs. positive control), but not siRNA to Smad3
(Fig. 10B and C). Representative blots and results are
summarized in Figure 10. Conversely, unphosphorylated
and phosphorylated forms of MAP kinases JNK1/2,
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Fig. 7. Effect of relaxin (RLX) on secretion of matrix metallopro-
teinase 2 (MMP-2) and MMP-9. The effect of relaxin on MMP secre-
tion was evaluated by gel zymography of cell supernatants. Experiments
were performed after incubation with three different concentrations of
relaxin (0.1, 1, and 10 ng/mL) for 48 hours. Iscove’s medium served as
control. Relaxin had significant stimulatory effects on MMP-2 secretion
(A) in both, Tk 173 (dark shading) and 188 (white shading). MMP-9 se-
cretion was also stimulated by relaxin (B), where the effect on Tk 188
was more robust than in Tk 173. Values are given in percentage of con-
trol and are the mean of six (Tk 173) and three (Tk 188) independent
experiments. Also one representative zymography for each cell line is
shown. ∗P < 0.05; ∗∗P < 0.01.
ERK, and p38 MAP kinase were not affected by stimu-
lation with relaxin in the presence or absence of TGF-b1
(Fig. 11).
DISCUSSION
Tubulointerstitial fibrosis is the final common path-
way of almost all forms of chronic progressive renal
disease [2]. An effective antifibrotic therapy should in-
hibit all parts of renal fibrogenesis, including fibroblast
proliferation, differentiation into myofibroblasts, ECM
synthesis, and matrix degradation. The peptide hormone
relaxin has already shown antifibrotic properties on der-
mal, cardiac, and pulmonary fibroblasts [15, 16]. How-
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Fig. 8. Influence of relaxin (RLX) on transforming growth factor-b1
(TGF-b1)–induced Smad2 (A) and Smad3 phosphorylation (B). Hu-
man renal fibroblasts were incubated with 10 ng/mL TGF-b1 and three
different concentrations of relaxin (0.1, 1, and 10 ng/mL) for 60 min-
utes. Single stimulation with TGF-b1 served as positive control (PC),
Iscove’s medium as negative control (NC). In Tk 461 primary human
renal fibroblasts, relaxin inhibited Smad2 phosphorylation at all inves-
tigated concentrations (A), but there were no effects on Smad3 phos-
phorylation. Since the antibody against pSmad3 cross-reacts with phos-
phorylated Smad1, 5, and 8, proteins were immunoprecipitated with
a Smad3-specific antibody prior to immunoblot analyses (IP Smad3).
Values are given in percentage of positive control and are the mean of
four independent experiments. Also one representative blot is shown.
∗P < 0.05 vs. negative control; ∗∗P < 0.05 vs. positive control.
ever, fibroblasts from different origins may display sub-
stantial heterogeneity [26].
Our results show that relaxin may inhibit fibroblast pro-
liferation (albeit moderately) and the TGF-b1–induced
transformation of these cells to myofibroblasts. More-
over, robust inhibitory effects of relaxin on TGF-b1–
induced collagen type I and fibronectin synthesis and se-
cretion could be demonstrated in human lung fibroblasts
[16], rat cardiac [27], and very recently in rat renal cortical
fibroblasts [28]. Those results implicate strong antifibrotic
properties. It has been demonstrated, that fibronectin is
able to activate latent TGF-b [29]. Thus, an inhibition of
fibronectin synthesis and secretion does inhibit fibrosis
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Fig. 9. Influence of relaxin (RLX) on transforming growth factor-b1 (TGF-b1)–induced Smad2 translocation (A), heteromer formation between
Smad2 and 3 (B), and expression of Smad7 (C). Human renal fibroblasts (Tk 173 and 188) were incubated with 10 ng/mL TGF-b1 and three
different concentrations of relaxin (0.1, 1 and 10 ng/mL) for 60 minutes. Single stimulation with TGF-b1 served as positive control (PC), Iscove’s
medium as negative control (NC). Cytosolic and nuclear proteins were isolated and cytosolic and nuclear Smad2 was detected by immunoblot
analysis. In Tk 188 relaxin inhibited shift of Smad2 from cytosol to nucleus (A). In (B) isolated proteins were immunoprecipitated for Smad2 and
immune complex bound Smad3 was detected by immunoblot after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). In Tk
188 human renal fibroblasts, relaxin reduced complex formation between Smad2 and 3 at all concentrations. Total cellular Smad2 and 3 expressions
were taken as internal controls. Values are given in percentage of negative control and are the mean of four independent experiments. Also one
representative blot is shown. ∗P < 0.05 vs. negative control; ∗∗P < 0.05 vs. positive control. There were no effects of relaxin on inhibitory Smad7
expression detectable (C).
by two mechanisms. First, it decreases ECM deposition
and second, it results in reduced matrix expression by di-
minishing TGF-b activity. However, those effects could
mainly prevent the development of renal fibrosis but they
are not useful to improve organ function by degrading
ECM depositions. Therefore we investigated the influ-
ence of relaxin on matrix degrading MMPs. Relaxin was
able to raise the secretion of MMP-2 and MMP-9 robustly.
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Fig. 10. Relaxin (RLX) as well as siRNA to Smad2, but not siRNA to Smad3 exert comparable inhibitory effects to fibronectin synthesis in Tk 188
renal fibroblasts. (A) Effective transfection with inhibitory RNA to Smad2 and Smad3 (siRNA) was demonstrated by a decreased Smad2 or Smad3
expression, respectively, after 48 hours of incubation with siRNA. (B) Effects of relaxin in comparison to siRNA to Smad2 or Smad3, respectively,
on transforming growth factor-b1 (TGF-b1)–induced fibronectin synthesis was demonstrated. Values are given in percentage of negative control
and are the mean of three independent experiments (C). ∗P < 0.05 vs. negative control; ∗∗P < 0.05 vs. positive control.
In murine pulmonary fibroblasts an increase of MMP-1
and MMP-2 has been reported before [16]. Surprisingly,
MMP-1 and MT-MMP-1 protein expression could not be
demonstrated in any of the investigated human renal fi-
broblasts indicating that they do not seem to play a role
in these cells.
All those results suggest powerful antifibrotic proper-
ties of relaxin also in vivo. Relaxin showed robust antifi-
brotic effects in in vivo models of pulmonary [16] and
renal fibrosis [19] as well as well as in a clinical trial of
patients with progressive systemic sclerosis [21]. In the
treatment of chronic renal failure relaxin might act due
to an additional effect. Danielson, Sherwood, and Con-
rad [14] were able to demonstrate that relaxin attenuates
Ang II–induced renal vasoconstriction. Consequently, re-
cently Garber et al [29] noted beneficial effects of relaxin
in two models of renal mass reduction. Interestingly, these
effects were in part dependent of its effects on blood pres-
sure reduction and in part independent of vasodilation.
McDonald et al [20] recently demonstrated that relaxin
may increase ubiquitin-dependent fibronectin degrada-
tion. In that study, decreased glomerular and interstitial
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Fig. 11. Relaxin (RLX) has no influence on transforming growth
factor-b1 (TGF-b1)–induced phosphorylation of mitogen-activated pro-
tein (MAP) kinases, extracellular-regulated protein kinase (ERK1/2)
(A), p38 MAP kinase (B), and c-Jun NH2 terminal kinase (JNK1/2)
(C). Human renal fibroblasts were incubated with 10 ng/mL TGF-b1
and three different concentrations of relaxin (0.1, 1, and 10 ng/mL) for
60 minutes. Single stimulation with TGF-b1 served as positive control,
Iscove’s medium as negative control (NC). There were no detectable
effects of relaxin on TGF-b1–induced phosphorylation of MAP kinases.
scarring was noted in a rat model of antiglomerular base-
ment membrane disease when the animals were treated
with relaxin. Moreover, Samuel et al [18] were able to
demonstrate that relaxin−/− mice displayed progression
in age-related fibrosis (albeit only in male animals) and
that this process could be reversed by addition of relaxin,
providing additional evidence for an antifibrotic effect of
the hormone.
Interestingly, some of the effects of relaxin we observed
were not purely dose-dependent. In most cases the most
robust effects were seen at dosages of 0.1 and 1 ng/mL
relaxin, the range of physiologic serum concentrations in
human pregnancies. These findings correspond to those
of Danielson, Sherwood, and Conrad [14] in a clinical
trial of relaxin in scleroderma patients and some of the
findings by McDonald et al [20]. It is tempting to spec-
ulate that they may be explainable by a receptor down-
regulation or by a relaxin molecule aggregation at higher
relaxin concentrations.
As described above, it is not much known about how
relaxin exerts its mechanisms since the exact nature
of the relaxin-receptor is still unknown. Recently, re-
ceptor binding and activation of orphan receptors by
relaxin has been demonstrated [30] although the signif-
icance of this finding for the effects of relaxin remains
to be determined. Moreover, relaxin may bind to gluco-
corticoid receptors, as was recently shown by Dschiet-
zig and Stangl [31]. In view of these facts, we indirectly
demonstrated specific cellular responses of renal fibrob-
lasts. Considering that relaxin is an insulin-like hormone
and that the insulin receptor is a tyrosine kinase, we in-
vestigated cellular tyrosine phosphorylation in depen-
dence of relaxin stimulation. In fact, we could demon-
strate a relaxin-induced tyrosine phosphorylation of a
>220 kD protein. Based on these results, we postulate
that the phosphorylated >220 kD protein may repre-
sent a relaxin receptor. In a next step we investigated
the influence of relaxin on TGF-b1 receptor interaction
and signal transduction pathways. In a first set of ex-
periments we could demonstrate, that relaxin does not
interfere with TGF-b1 receptor binding. The central sig-
nal transduction pathway of TGF-b molecules is medi-
ated by Smad proteins. There exists a common mediator
Smad, Smad4. Besides Smad4, the most important Smad
proteins for the TGF-b1 signal transduction are Smad2
and 3 as well as the inhibitory Smad7. The cytosolic re-
ceptor Smad2 and 3 are activated by type I TGF-b re-
ceptor and become phosphorylated. Subsequently, they
form heteromeric complexes either as Smad2/Smad4,
Smad3/Smad4, or as Smad2/Smad3/Smad4. These re-
ceptor Smad/costimulatory Smad heteromeric complex
translocates to the nucleus where they bind to DNA.
Furthermore the TGF-b1 signaltransduction is mod-
ulated by MAP kinase pathways via p38, JNK, and
ERK. Consequently, the influence of relaxin on all those
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proteins was investigated. Relaxin had no influence on
cellular amounts of Smad4 and Smad7 as well as on phos-
phorylated or unphosphorylated forms of MAP kinases
JNK1/2, ERK, or p38 MAP kinase. However, relaxin had
distinct inhibitory effects on TGF-b1–induced Smad2
phosphorylation resulting in a reduction of transloca-
tion of Smad2, but neither on Smad3 phosphorylation
nor translocation of Smad3 from cytosol to the nucleus
and, moreover, a reduction of heteromeric formation be-
tween Smad2 and Smad3 as could be demonstrated by
the results of the immunoprecipitation studies. Those re-
sults suggest that relaxin affects TGF-b1 signal transduc-
tion through an inhibition of receptor regulated Smad2,
whereas Smad3, Smad4, or inhibitory Smads were un-
affected. Further proof for the specificity of this effect
is provided by the fact that inhibition of Smad2 with
siRNA resulted in similar results, whereas siRNA to
Smad3 did have no noticeable effect on TGF-b1–induced
fibronectin synthesis. There is some controversy in the
literature regarding the mediation of TGF-b1–mediated
fibronectin synthesis and secretion. Whereas our results
seem to confirm findings by Isono et al [32] in mesangial
cells, others have described that fibronectin synthesis may
be independent of the Smad pathway in mouse embryo
fibroblasts [33] and a rat fibroblast cell line [34]. Possibly,
species differences may explain the differences observed.
CONCLUSION
We conclude that relaxin may represent a potent ther-
apeutic agent to reverse renal fibrosis and remodel renal
function. Those properties are at least in part mediated
by an attenuation of the profibrotic TGF-b1 effects. Fur-
ther studies are necessary to delineate the exact nature of
the interaction between relaxin and TGF-b1 signal trans-
duction pathways.
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